BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Ghent, BELGIUM – 10 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live webcast at 02:00 pm CET / 08:00 am EST on the day of the results. The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on the Company’s website shortly thereafter. For more information, please contact: Sequana Medical Lies Vanneste Director Investor Relations Tel: +32 498 05 35 79 Email: IR@sequanamedical.com LifeSci Advisors Chri